EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Reactive oxygen species: Janus-faced molecules in the era of modern cancer therapy

Aine O'Reilly, Wenchao Zhao, Stina Wickström iD, Elias S J Arnér, Rolf Kiessling iD

Journal for ImmunoTherapy of Cancer · 2024-12 · 12 (12) · e009409

DOI: 10.1136/jitc-2024-009409 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 07.12.2024. Verfasst von Aine O'Reilly und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Neoplasms, Reactive Oxygen Species. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 175 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Swedish Medical Research Council, The Swedish Cancer Society, The Hungarian National Research, Development and Innovation Office (NKFIH) under the National Laboratories Program (National Tumor Biology Laboratory)..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oxidative stress, that is, an unbalanced increase in reactive oxygen species (ROS), contributes to tumor-induced immune suppression and limits the efficacy of immunotherapy. Cancer cells have inherently increased ROS production, intracellularly through metabolic perturbations and extracellularly through activation of NADPH oxidases, which promotes cancer progression. Further increased ROS production or impaired antioxidant systems, induced, for example, by chemotherapy or radiotherapy, can preferentially kill cancer cells over healthy cells. Inflammatory cell-derived ROS mediate immunosuppressive effects of myeloid-derived suppressor cells and activated granulocytes, hampering antitumor effector cells such as T cells and natural killer (NK) cells. Cancer therapies modulating ROS levels in tumors may thus have entirely different consequences when targeting cancer cells versus immune cells. Here we discuss the possibility of developing more efficient cancer therapies based on reduction-oxidation modulation, as either monotherapies or in combination with immunotherapy. Short-term, systemic administration of antioxidants or drugs blocking ROS production can boost the immune system and act in synergy with immunotherapy. However, prolonged use of antioxidants can instead enhance tumor progression. Alternatives to systemic antioxidant administration are under development where gene-modified or activated T cells and NK cells are shielded ex vivo against the harmful effects of ROS before the infusion to patients with cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsReactive Oxygen SpeciesAnimalsHumansAntioxidantsImmunotherapyOxidative Stress

Stichwörter der Autor:innen

Immune modulatoryImmunosuppressionImmunotherapyTumor microenvironment - TME

Substanzen

AntioxidantsReactive Oxygen Species

Autor:innen und Institutionen

  • Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Department of Medicine, University College Cork, Cork, Ireland.
  • The Christie NHS Foundation Trust, Manchester, UK.
  • Division of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
  • Theme Cancer, Patient area Head and Neck, Lung and Skin, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Selenoprotein Research and the National Tumor Biology Laboratory, National Institute of Oncology, Budapest, Hungary.

ORCID-Profile: Stina Wickström, Rolf Kiessling

Förderung

  • The Swedish Medical Research Council
  • The Swedish Cancer Society
  • The Hungarian National Research, Development and Innovation Office (NKFIH) under the National Laboratories Program (National Tumor Biology Laboratory).
  • the Hungarian Thematic Excellence Program
  • The Cancer Society in Stockholm

Zitieren

APA

O'Reilly, A., Zhao, W., Wickström, S., Arnér, E. S. J., & Kiessling, R. (2024). Reactive oxygen species: Janus-faced molecules in the era of modern cancer therapy. Journal for ImmunoTherapy of Cancer, 12(12), e009409. https://doi.org/10.1136/jitc-2024-009409

Vancouver

O'Reilly A, Zhao W, Wickström S, Arnér ESJ, Kiessling R. Reactive oxygen species: Janus-faced molecules in the era of modern cancer therapy. Journal for ImmunoTherapy of Cancer. 2024;12(12):e009409. doi:10.1136/jitc-2024-009409

BibTeX
@article{OReilly2024,
  author = {O'Reilly, Aine and Zhao, Wenchao and Wickström, Stina and Arnér, Elias S J and Kiessling, Rolf},
  title = {Reactive oxygen species: Janus-faced molecules in the era of modern cancer therapy},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  volume = {12},
  number = {12},
  pages = {e009409},
  doi = {10.1136/jitc-2024-009409}
}
Kostenlos starten →